Pfizer Sees Expanded Access To Paxlovid With Pharmacist Prescribing
Executive Summary
Giving prescribing authority to pharmacists could improve access to the antiviral for patients at high risk for severe COVID-19. Comirnaty financial outlook is also strengthened based on new US contract.
You may also be interested in...
Pfizer’s COVID-19 Franchise Dominates Best-Seller List
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a fast riser while Comirnaty and Moderna’s Spikevax saw declining sales. Pfizer's two COVID-19 products netted £46bn in total.
Pharma Q2 Preview: Demonstrating Resiliency Against A Turbulent Backdrop
Inflation, rising interest rates, market volatility, violence in Ukraine and a persistent pandemic created a chaotic macroenvironment for doing business. Pharma appears poised to grow, nonetheless.
Deal Watch: Sanofi Offloads Established Products, Lilly Testing 3D-Printed Drugs
Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.